A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy

Inclusion Criteria: * (Fe) male \>, = 18 years * Fibrosing skin disorder, not fulfilling the ACR criteria for diffuse SSc * Inadequate response to methotrexate (at least 12 weeks 10 mg/w, except if not tolerated or contra-indicated * Debilitating disease defined by either one of the following: * Restriction of mobility * Disfiguration: eg: facial involvement * Severe Internal Organ involvement * Contraception for women with childbearing potential. Sexual abstinence is an alternative to contraception. Exclusion Criteria: * FVC\<, = 50% * LVEF\<, = 40% of predicted value, * DLCO\<, = 40% of predicted value * Exclusion criteria as specifically described in the protocol for anti-CD-20: * Lack of peripheral venous access. * Pregnancy or breast feeding. * Significant cardiac or pulmonary disease (including obstructive pulmonary disease). * Evidence of significant uncontrolled concomitant disease such as, but not limited to, nervous system, renal, hepatic, endocrine or gastrointestinal disorders which, in the investigator's opinion, would preclude patient participation. * Primary or secondary immunodeficiency (history of, or currently active), including known history of HIV infection. * Known active infection of any kind (excluding fungal infections of mail beds), or any major episode of infection requiring hospitalization or treatment with i.v. anti-infectives within 4 weeks of baseline or completion of oral anti-infectives within 2 weeks prior to baseline. * History of deep spa…